Antibodies are the proteins produced by B-cells (in the bone marrow) in the immune system. These proteins attach themselves to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies, which attach themselves to different sites of an antigen. mAbs are monospecific, as they are the clones of a single parent cell. They are complex proteins with high molecular weight, and were first developed in 1975 by Kohler and Milstein. mAbs are generally of three types, chimeric, humanized, and fully human, and are often used for therapeutic and diagnostic purposes.

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Assumptions

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: mAbs: Overview

Evolution of mAb therapeutics

Types of mAbs

Conjugated cancer therapies using mAbs

PART 06: Market landscape

Market overview

Five forces analysis

PART 07: Market segmentation by type of mAbs

Naked mAbs

Conjugated mAbs

PART 08: Market segmentation by application

Global oncology mAbs market

Global autoimmune and inflammatory mAbs market

TNF inhibitors

IL-1 blockers

PDE4 inhibitors

Global respiratory mAbs market

Global ophthalmology mAbs market

PART 09: Geographical segmentation

Global mAbs market by geographical segmentation

2015-2020

mAbs market in Americas

mAbs market in US

mAbs market in EMEA

mAbs market in APAC

PART 10: Key leading countries

PART 11: Pipeline portfolio

PART 12: Market drivers

Reimbursement benefits for mAbs and its biosimilars

Special regulatory drug designations

Increase in demand for ADCs

Increase in industry-academia collaborations

PART 13: Impact of drivers

PART 14: Market challenges

Absence of adequate diagnosis and screening

procedures

High manufacturing costs coupled with stringent

regulations

Threat from chemotherapy and off-label drugs

Difficulties in patient recruitment for conducting clinical

trials

PART 15: Impact of drivers and challenges

PART 16: Market trends

Emergence of biosimilars

Growing focus of vendors on untapped markets

Focus on novel mechanisms

Joint ventures and partnerships for R&D

Emergence of targeted and combination therapies

PART 17: Vendor landscape

Competitive scenario

Key news

F. Hoffmann-La Roche

AbbVie

Johnson & Johnson

Amgen

Merck

BMS

Other prominent vendors

PART 18: Appendix

List of abbreviations

PART 19: Explore Technavio